Aim: To test the hypothesis that men of black (West) African ethnicity (black African men [BAM]) with early type 2 diabetes (T2D) would have greater insulin secretory deficits compared with white European men (WEM), following prediabetic hypersecretion.
| INTRODUCTION
Populations of African ancestry are disproportionately affected by type 2 diabetes (T2D) 1 ; it develops at a younger age 2 and at a lower body mass 3 in black people than in white people.
The main pathophysiological processes of insulin secretory failure and insulin resistance that underlie T2D are well documented, 4 but differences in the pathogenesis based on ethnicity are increasingly recognized. There is a growing amount of literature examining metabolism in black populations without diabetes, with studies in African-American children and adolescents without diabetes describing marked hyperinsulinaemia compared with other ethnicities, [5] [6] [7] [8] [9] [10] [11] and extensive reports that black populations, both indigenous 12 and diasporic, [13] [14] [15] [16] [17] [18] [19] exhibit a hyperinsulinaemic response to glucose. Conventionally, hyperinsulinaemia is understood to occur in response to heightening insulin resistance, but this does not fully explain the response in black populations. 6, 9, 11 Studies in children measuring Cpeptide have described a combination of increased insulin secretion and reduced hepatic insulin clearance. 7, 9 Studies in healthy and prediabetic adults have shown lower rates of insulin clearance, 13, 15, 19 but heterogeneity in the populations has made independence from insulin resistance and body weight/composition differences difficult to ascertain. If intensified hyperinsulinaemia represents greater insulin secretion, it may predispose to earlier β-cell exhaustion in the development of T2D. To date, no studies have undertaken comparisons of β-cell function in black African and white European populations with recent-onset T2D. As this may be the time people first present to health services, this is an important phase to understand.
The measurement of insulin secretory capacity is complex. Techniques based on the measurement of circulating insulin concentrations only partially reflect insulin secretion and fail to account for hepatic insulin clearance. Measurement of C-peptide overcomes this and reflects more precisely true pancreatic insulin secretion. The intravenous glucose tolerance test is the most commonly used method, but it is often restricted to assessing only first-phase secretion. The hyperglycaemic clamp is a more rigorous method that distinguishes first-and second-phase secretion; however, it does not account for the role of incretin hormones, which can be assessed by a meal tolerance test.
The aim of the present study was to assess insulin secretory function comprehensively, in response to both intravenous and oral stimulation, in order to explore the hypothesis that men of black (West) African ethnicity (black African men [BAM]) will have significantly greater insulin secretory deficits than white European men (WEM) by the time they manifest T2D.
| PARTICIPANTS AND METHODS
The study was conducted at the Clinical Research Facility, King's College London, UK and was approved by the London Bridge National
Research Ethics Committee (12/LO/1859); all participants provided informed consent. Recruitment and data collection took place in April 2013 to January 2015.
| Participants
Participants were BAM and WEM (ethnicity self-declared, confirmed by grandparental birthplace), aged 18 to 65 years, with a body mass index (BMI) 25 to 35 kg/m 2 , a documented diagnosis of T2D within 5 years, treated with lifestyle advice AE metformin, and a glycated haemoglobin (HbA1c) concentration ≤ 63.9 mmol/mol (<8%), and were recruited from South London General Practices taking part in an early detection T2D screening programme. 20 Participants were deemed ineligible if they: were treated with other diabetes medications, chronic oral steroids or β-blockers; had a serum creatinine concentration > 150 mmol/L; had a serum alanine transaminase level > 2.5 times above the upper limit of the reference range; had positive auto-antibodies for anti-insulin, anti-glutamic acid decarboxylase or anti-A2; had sickle cell disease (trait permitted); or were taking medications believed to affect the outcome measures.
Participants completed a medical screening before study entry. BAM were matched with WEM for age (AE5 years) and BMI (AE3 kg/m 2 ).
| Study design
Assessment visits were completed in random order and separated by a minimum of 7 days. For each assessment, participants arrived having refrained from eating or drinking anything other than water from 10:00 PM the night before. Participants were instructed to refrain from strenuous exercise and physical activity in the preceding 48 hours and from alcohol in the preceding 24 hours, and to consume a standardized diet the day before (~50% of calories from carbohydrate, evenly spread throughout the day, with no more than 30% of daily carbohydrate consumed in the evening meal). Participants on metformin were instructed to cease taking it for 7 days prior to the visit. The area under the curve (AUC) and incremental AUC (iAUC)
were calculated, using the trapezoidal rule, for insulin, C-peptide, glucose, NEFA, GLP-1 and GIP. To calculate an index of first-and second-phase insulin secretion in the hyperglycaemic clamp we measured the iAUC for C-peptide over 0 to 10 minutes for first-phase, and 10 to 120 minutes for second-phase insulin secretion, similarly
to DeFronzo et al. 21 Model-based measurement of β-cell function: the glucose, insulin and C-peptide curves during the hyperglycaemic clamp and meal tolerance test were modelled using methods previously described [23] [24] [25] (SAAM-II 1. In both the hyperglycaemic clamp and meal test, average insulin clearance was computed according to the following formula (derivation and correct interpretation are presented in the File S1):
in which AUC ISR is the area under the curve of insulin secretion rate, AUC I is the area under the curve of insulin concentration, I Final is insulin concentration at the end of the study, I Basal is insulin concentration at the beginning of the study, and MRT Ins is the mean residence time of insulin, which was assumed to be 27 minutes as reported in Navalesi et al. 26 The reconstructions of β-cell function during the hyperglycaemic clamp and the meal tolerance test were combined to enable modelling of the effect of incretins on insulin secretion: the "meal effect."
This was done by taking the β-cell reconstructed from the hyperglycaemic clamp and challenging it, in an in silico experiment, with the plasma glucose curve of the meal test, thus computing the time course and the total amount of insulin secretion rate; this is the in silico equivalent of infusing in vivo intravenous glucose to mimic the glucose curve seen during the meal tolerance test. The effect of the meal on β-cell insulin secretion can be measured by comparing the total insulin secretion of the meal in vivo with that of the in silico simulation of intravenous glucose infusion to mimic the glucose curve elicited by the meal test:
Further details of the computation of the "meal effect" are provided in the File S1-S7.
| Statistics
All datasets were tested for normality (Shapiro-Wilks test) and nonnormally distributed variables were transformed (log 10) for analysis.
Normally distributed data are expressed as mean AE SD, and log-normal data were back transformed to give geometric mean and 95% CI for the ratio of the geometric mean. Differences between ethnic groups were determined by independent samples t test using the raw data where they were normally distributed or logarithmic-transformed data where not. P values ≤.05 were considered statistically significant. Note that for the data analysed on the natural scale, the null value is 0 and so where P < .05, the 95% CI will exclude 0, but for the data analysed on the log scale and back-transformed to give the ratio of geometric means, the null value is 1 and so where P < .05, the 95% CI will exclude 1. The relationship between average insulin clearance and average insulin concentration was analysed by linear and non-linear regression analysis, as described in the File S1. Analyses were performed using SPSS software, version 24 (IBM Analytics).
| RESULTS
A total of 34 participants, 19 BAM and 15 WEM, were studied. Their mean (SD) age was 54.7 9 (7.4) years and BMI 29.7 (2.7) kg/m 2 . The participants had been diagnosed with diabetes for 2.9 (1.1) years, the mean HbA1c was 49.3 (7.6) mmol/mol; 65% of participants were treated with metformin and the remainder with lifestyle management alone. By design, there were no significant ethnic differences in age, BMI, duration of diabetes, HbA1c, or management (Table 1) . Mean visceral fat was significantly lower, and skeletal muscle area significantly higher in BAM ( Table 1) . The BAM were first-generation West
African migrants (born in Nigeria, n = 11; Ghana, n = 5; Sierra Leone, n = 2; Ivory Coast, n = 1).
| β-Cell insulin secretory function
In the hyperglycaemic clamp there were no ethnic differences in mean fasting ( (Table 2 ). There were no significant ethnic differences in firstphase C-peptide or insulin iAUC. Second-phase C-peptide secretion (iAUC) was significantly lower in BAM, with a trend for second-phase insulin iAUC that did not achieve statistical significance ( Figure 1 and Table 2 ). The modelled glucose sensitivity of the β-cell (σ 1 and σ
)
showed similar trends.
During the meal tolerance test the two ethnic groups exhibited the same glucose response; however, mean C-peptide iAUC was significantly lower in BAM. The meal insulin iAUC was not significantly different between ethnic groups (Table 3 and Figure 2 ). The modelled data from the meal tolerance test showed no significant ethnic differences in first-phase insulin secretory function (Table 3) , but secondphase secretory function was lower in BAM (P = .01). The insulin secretion rate was lower amongst BAM at 4 mmol/L (P = .019) and 5.5 mmol/L (P = .02). This difference was lost at higher glucose concentrations of 8 mmol/L (P = .112), 11 mmol/L (P = .199) and 15 mmol/L (P = .247; Figure 3 ).
| Insulin clearance
There were no ethnic differences in average insulin clearance during the intravenous challenge (hyperglycaemic clamp; Table 2 ). In response to oral glucose the average clearance appeared lower in BAM, but this difference was not statistically significant (Table 3) .
When average clearance was plotted against average insulin concentration of each test, however, a hyperbolic relationship was apparent , glucose sensitivity of β cell during second-phase insulin secretion; BAM, black African men; BMI, body mass index; BSA, body surface area; CI, confidence interval; iAUC, incremental area under the curve, calculated using the trapezoidal rule; M, glucose disposal in final 60 minutes of the clamp; WEM, white European men. iAUC 0 to 10 min represents first phase, iAUC 10 to 120 min represents second phase. Data are mean (SD) or geometric mean (95% CI) for log-normal data*. Positively skewed data were transformed (log 10 ) prior to statistical testing. Differences between ethnic groups tested using independent samples t test. Bold font was used to highlight findings with a statistically significant probability.
( Figure S8 in File S1), with a clear, significant difference between the groups, implying that in BAM average insulin clearance was lower at any average insulin concentration achieved during meal/clamp tests (Figure 4 ).
| Incretin responses
Mean secretion of GIP was significantly higher in BAM in response to the meal challenge (Table 3 ). There were no ethnic differences in GLP-1 secretion, or in the "meal effect," the modelled effect of the mixed meal, including incretin hormones, on insulin secretion (Table 3) .
| DISCUSSION
The present study shows differences in the metabolic processes involved in glucose dysregulation in BAM with early T2D compared The present study provides the most comprehensive assessment of the impact of black ethnicity on β-cell function to date. We used the intravenous glucose challenge of the hyperglycaemic clamp to distinguish first-and second-phase secretion, whilst the meal tolerance test was used to assess the physiological response of the β cells to nutrients, and incretin effects. In the present study we observed significantly lower fasting C-peptide concentrations amongst BAM, compared with WEM who had a similar duration of diagnosed diabetes, indicating significantly greater reduction in basal insulin secretion, although circulating insulin concentrations were not different. We also found reduced second-phase insulin and C-peptide response to intravenously stimulated hyperglycaemia amongst BAM. Previous studies assessing insulin secretion in non-diabetic populations, have provided inconsistent findings 7,10,11 ; reporting higher first-and second-phase secretion, 8 or the difference occurring only in the first 6 or second phase. 5 In the aetiology of T2D, impairments in both firstand second-phase insulin responses have been recognized. 27, 28 The second-phase response, which can only be triggered and sustained by glucose and fuel secretagogues, is quantitatively very important in the maintenance of glucose homeostasis, given that it can be sustained in response to prolonged hyperglycaemia. 29 Our modelling methods enabled us to investigate the impact of ethnicity on glucose dose effects on insulin secretion, which have not previously been examined amongst populations of African ancestry. Interestingly, ethnic differences in second-phase insulin secretion rates at lower glucose levels were lost at higher glucose concentrations (>8 mmol/L).
Since both basal and glucose tolerance are similar in the two groups, this result suggests that, in the post-absorptive state, insulin secretion plays a different adaptive role in the two groups.
We are not aware of other studies comparing β-cell function between BAM and WEM with T2D using the hyperglycaemic clamp.
The majority of ethnic comparisons have focused on healthy individuals or those at increased risk of T2D, and have predominantly used the intravenous glucose tolerance test to measure the "acute insulin response," which is comparable to the first-phase response of the hyperglycaemic clamp, but often only insulin is measured and rarely is the second-phase response assessed. These investigations have consistently shown a higher acute insulin response among black people without diabetes. [5] [6] [7] 15, 30, 31 To date, only one comparison has been performed in people with T2D of different ethnicity, the Insulin
Resistance Atherosclerosis Study (IRAS), 14 which reported significantly higher acute insulin response among black people than in white people, although not among the participants with newly diagnosed T2D, who are a nearer comparison to the participants in the present study. Notably, IRAS did not assess C-peptide so it is not possible to determine β-cell secretion, and the second-phase response was not assessed. There are other distinctions. It is well Meal effect (%) 51.0 (12.9) 49.5 (6.4) 1.5 (−6.2-9.1) .700
Abbreviations: σ 1 , glucose sensitivity of β cell during first-phase insulin secretion; BAM, black African men; GIP, gastric inhibitory polypeptide; iAUC, incremental area under the curve, calculated using the trapezoidal rule; NEFA, non-esterified fatty acids; WEM, white European men. Data are mean (SD) or geometric mean (95% CI) for log-normal data * . Positively skewed data transformed (log 10 ) prior to statistical testing. Differences between ethnic groups tested using independent samples t test. Bold font was used to highlight findings with a statistically significant probability.
established that the phenotype of T2D in black populations is gender-specific 16, 17 ; higher insulin levels 16, 17 and obesity-driven T2D are more common in women, 16 hence the present study included only men, whereas IRAS included both men and women. There is a need for further studies to examine gender-specific mechanisms.
Our findings of significantly lower basal C-peptide but not insulin raise concerns regarding the use of β-cell indices based on fasting insulin, such as HOMA-β. 32 These are often used to assess β-cell function in epidemiological studies but our data suggest they may misrepresent β-cell function in black populations, and findings of ethnic differences 16 may need to be considered with caution.
When we studied β-cell function using an oral stimulus, we recognized a significantly lower second-phase C-peptide response in BAM, consistent with the hyperglycaemic clamp; however, there were no differences in insulin concentrations and model-derived data found to indicate lower insulin clearance in BAM (Figure 4 ). The implication of Figure 4 is that, at the same total insulin output during an intravenous or an oral challenge, BAM achieve higher insulin curves, which may compensate for reduced β-cell secretion and contribute to peripheral insulin levels. A number of previous investigations have reported reduced insulin clearance in black populations without diabetes, [5] [6] [7] 13, 15, 33 and, in the present study, we show that this is maintained into early T2D. The mechanisms underlying this are largely unknown, but recent advancements in modelling techniques that allow hepatic vs extrahepatic clearance to be quantified have concluded that ethnic differences in insulin clearance are solely hepatic with no extra-hepatic contribution. 34 A reduction in insulin clearance is typically found after oral glucose or meal ingestion, and is characteristically of a much greater magnitude than that observed after intravenous induction of hyperglycaemia. [35] [36] [37] Reduction in insulin clearance with increasing levels of insulin secretion is proposed to be attributable to the saturable nature of hepatocellular insulin receptors 38, 39 ; however there is also evidence that incretin hormones affect insulin clearance. 36, 37, 40 There has been very little study of incretin hormones and how these vary according to ethnicity. In the present study, BAM exhibited significantly higher postprandial GIP concentrations, which may have contributed to the non-significant trend for lower average insulin clearance that was observed. The effect of insulin clearance-reducing effect of GIP, 41, 42 whilst others have shown no effect. 39, 43 Some of the conflict in these findings may have occurred because insulin clearance appears to adapt to insulin resistance and glucose intolerance, a potential mechanism by which β-cell function is preserved in the progression to T2D. 44, 45 There has been very little investigation of incretin hormones within black populations and, in the few studies that exist, the focus has been on the role of incretins in the upregulation of insulin secretion; African-American children have been reported to have lower GLP-1, but similar GIP secretion compared with European-American children 46 whereas in a study of black and white obese adolescents, Michaliszyn et al 33 reported no difference in GLP-1 or GIP levels, while Velasquez-Mieyer et al 47 found higher GLP-1 levels in obese African-American adults compared with European-Americans, with no measurement of GIP. We modelled the impact of the mixed meal, including, but not limited to, the effect of the incretin response on insulin secretory function ("meal effect"), but detected no ethnic differences. Michaliszyn et al 33 modelled the "potentiation factor," which describes the modulation of the relationship between glucose concentration and insulin secretion and comprises several mechanisms, including the release of endogenous incretin hormones. In contrast to our data, they found no differences in incretin concentrations in response to an oral glucose challenge, but reported a significantly higher early potentiation factor in black participants. 33 Our data suggest that, by the time diabetes develops, BAM may have no greater β-cell response to GIP than WEM, but that their higher GIP response may cause lower average insulin clearance in response to hyperglycaemia, which results in maintenance of peripheral insulin concentrations, and that these mechanisms provide some compensation for the significantly lower insulin secretory capacity of the β cells.
The strengths and limitations of the present study warrant discussion. We did not investigate the cellular mechanisms that underlie the differences in metabolic function between BAM and WEM. Additionally, we only captured the metabolic phenotype of T2D, and of men, therefore we cannot allude to the mechanisms by which hyperglycaemia progresses and how this may be distinct among BAM, and our findings may not extrapolate to women. Our study has explored ethnic differences in insulin secretory function and in doing so has a priori assessed a comprehensive portfolio of measures that attempt to thoroughly characterize insulin secretory function. Although we conducted a large number of comparisons we did not correct for multiple testing because our outcome variables were not independent of one another and the differences were very large and highly significant; therefore, we are confident that the differences we observed are likely to represent real differences. Finally, the model used to aid computation of the meal effect on β-cell function (File S1) has not been validated with ad hoc experiments.
Major strengths of the study are its use of intensive, sophisticated techniques, and the well-matched participant groups; our ethnic groups had the same duration of diagnosed diabetes, HbA1c, fasting glucose and clinical management, and exhibited almost identical glucose responses to a meal challenge. We are therefore confident we have recognized novel ethnic distinctions in T2D pathophysiology, which may have important clinical implications. The intensive nature of our protocol precludes a much larger study, and we may have missed additional more subtle ethnic differences, but the value of our approach is perhaps best seen in the way our data extend the conclusions of epidemiological studies such as IRAS, dis- maintaining peripheral insulin concentrations by reducing insulin clearance in BAM. Meanwhile, it may be pertinent to consider therapeutic strategies that augment these physiological processes; BAM may achieve greater clinical benefit from therapeutic agents that support β-cell function, such as the incretin therapies.
